All In Biotech

Drug Trial Radar · NCT04238715

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

A Multicenter, Open-Label, Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR 2 Gene Fusion

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

63

Actual

Start

Jan 22, 2020

Primary completion

Nov 3, 2025

Study completion Nov 3, 2025

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Jan 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma with FGFR2 gene fusion who failed gemcitabine-based combination chemotherapy.

Conditions

  • Cholangiocarcinoma

Interventions

  • E7090Drug

    E7090 tablets orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: From first dose of study drug until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years 2 months)

Locations

56 sites in 2 countries. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Beijing Tsinghua Chang Gung Memorial Hospital

    Beijing, Beijing Municipality, China

  • Beijing Youan Hospital Affiliated to Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijng Cancer Hospital

    Beijing, Beijing Municipality, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking Union Medical University Hospital

    Beijing, Beijing Municipality, China

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Guangdong Province Traditional Chinese Medical Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital, Sun Yat-sen Univeristy

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Affilicataed Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan provincial people's hospital

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China

  • The First Affiliated Hospital of Soochow

    Suzhou, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Ningbo First Hospital

    Ningbo, Zhejiang, China

  • Eisai Trial Site 18

    Chiba, Japan

  • Eisai Trial Site 15

    Fukuoka, Japan

  • Eisai Trial Site 20

    Kagoshima, Japan

  • Eisai Trial Site 19

    Kochi, Japan

  • Eisai Trial Site 12

    Kyoto, Japan

  • Eisai Trial Site 21

    Niigata, Japan

  • Eisai Trial Site 24

    Wakayama, Japan

  • Eisai Trial Site 10

    Nagoya, Aichi-ken, Japan

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.